| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
3 companies
Degnan Chris is a Chief Financial Officer at Galera Therapeutics, Inc. with holdings across 3 companies. Recent SEC Form 4 filings include 2 buys and 1 sell.
Estimated insider holdings value: $158K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2025 | URGN Urogen Pharma Ltd. | Chief Financial Officer | Sale+OE | 2,203 | $16.85 | $37,120.55 | -49.1% | +26.3% | - | |
| Mar 13, 2023 | GRTX Galera Therapeutics, Inc. | Chief Financial Officer | Buy | 10,000 | $1.96 | $19,593.00 | New | - | - | |
| Jun 19, 2018 | VRCA Verrica Pharmaceuticals Inc. | Chief Financial Officer | Buy | 3,000 | $15.00 | $45,000.00 | New | - | - |